Certain A Shares of Shenzhen New Industries Biomedical Engineering Co., Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2023.
May 11, 2023
Share
Certain A Shares of Shenzhen New Industries Biomedical Engineering Co., Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2023. These A Shares will be under lockup for 1107 days starting from 30-APR-2020 to 12-MAY-2023.
Details:
The company director holding shares in the company Liu Peng, senior management Song Hongtao, Ding Chenliu, Zhang Xiaohong, Hu Daguang, Liu Haiyan, Li Tinghua and Zhang Lei, employee supervisor holding shares in the company Jiang Lili, employee shareholders directly holding shares in the company, a total of 99 persons including Li Lan and Yin Li (including 5 resigned employees and excluding the company's current senior management, employee representative supervisor Jiang Lili and Rao Wei's persons acting in concert Rao Jie, Hu Yi and Xu Dinghong) and a total of 37 shareholders of the company including Hainan Hengliya Industrial Co., Ltd., Ganzhou Yisheng Investment Partnership Enterprise (Limited Partnership), Zhongyi Jiakang (Tianjin) Investment Partnership Enterprise (Limited Partnership), and Bian Hao have agreed not to dispose of their interest for a period of 12 months from the date of listing.
The company holding stockholder, namely, Tibet New Industries Investment Management Co., Ltd., Shareholder holding more than 5% shares in the company - Tianjin Sequoia Juye Equity Investment Partnership Enterprise (Limited Partnership, actual controller and director Wen Xianding; shareholders holding more than 5% stake in the company, chairman of the board and general manager Rao Wein and Persons acting in concert of Rao Wei, namely, Rao Jie, Hu Yi and Xu Dinghong have agreed not to dispose of their interest for a period of 36 months from the date of listing.
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.